A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors IMPAX Laboratories
- 02 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Aug 2017.
- 02 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
- 07 Jul 2017 Status changed from recruiting to active, no longer recruiting.